Multiple Myeloma

• CLINICAL_TRIALS research · 2025-11-06
  Clinical Trial Update: Personalized NK Cell Therapy in CBT [Phase 2]

  A Phase 2 trial from MD Anderson is evaluating personalized NK cell therapy across several hematologic cancers. The study is currently recru…

• EMA approval · 2025-11-06
  EMA Authorised: Lenalidomide Mylan (lenalidomide) — Mylan Ireland Limited

  The European Medicines Agency authorised Lenalidomide Mylan (lenalidomide) by Mylan Ireland Limited for the treatment of multiple myeloma.

• CLINICAL_TRIALS trial_result · 2025-11-05
  Clinical Trial Update: Stem Cell Transplantation for Patients With Multiple Myeloma [Phase 1]

  A Phase 1 trial evaluating stem cell transplantation for patients with multiple myeloma has completed.

• CLINICAL_TRIALS research · 2025-11-04
  Clinical Trial Update: Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) [Phase 4]

  This Phase 4 clinical trial investigates whether Fenofibrate can prevent peripheral neuropathy induced by VRd (bortezomib, lenalidomide, dex…

• CLINICAL_TRIALS research · 2025-11-04
  Clinical Trial Update: Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis [Phase 2]

  A Phase 2 clinical trial evaluating whether siltuximab can reduce symptom burden after autologous stem cell transplantation in patients with…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2025-11-04
  Clinical Trial Update: Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) [Phase 2]

  A phase 2 MATCH subprotocol M trial update evaluating MLN0128 (TAK-228) as a targeted treatment for cancers with TSC1 or TSC2 genetic change…

• CLINICAL_TRIALS research · 2025-11-04
  Clinical Trial Update: Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) [Phase 2]

  This update describes a Phase 2 MATCH subprotocol evaluating larotrectinib (LOXO-101) in cancers with NTRK gene alterations; the trial statu…

• CLINICAL_TRIALS research · 2025-11-04
  Clinical Trial Update: A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma [Phase 1]

  This update describes an open Phase 1 trial evaluating TTI-622 in combination with Daratumumab Hyaluronidase-fihj for multiple myeloma, curr…

• CLINICAL_TRIALS trial_result · 2025-11-03
  Clinical Trial Update: Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies [Phase 2]

  Phase 2 trial evaluating nivolumab in patients with hematologic malignancies after CAR-T therapy; results have been posted with the study cu…

• CLINICAL_TRIALS trial_result · 2025-11-03
  Clinical Trial Update: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

  Phase 1 clinical trial evaluating the combination of selinexor, carfilzomib, and dexamethasone in relapsed or refractory multiple myeloma ha…

• CLINICAL_TRIALS trial_result · 2025-10-31
  Clinical Trial Update: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) [Phase 2]

  Phase 2 MATCH subprotocol update evaluating GSK2636771 for cancers with PTEN genetic changes; results were posted in 2025.

• CLINICAL_TRIALS research · 2025-10-31
  Clinical Trial Update: Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) [Phase 2]

  Phase 2 MATCH subprotocol Z1I study evaluating AZD1775 (adavosertib) as a targeted treatment for cancers with BRCA genetic changes. The tria…

• CLINICAL_TRIALS research · 2025-10-31
  Clinical Trial Update: Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) [Phase 2]

  Phase 2 MATCH subprotocol L clinical trial evaluating MLN0128 (TAK-228) for cancers with mTOR genetic changes; status is ACTIVE_NOT_RECRUITI…

• CLINICAL_TRIALS trial_result · 2025-10-30
  Clinical Trial Update: Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies [Phase 2]

  Phase 2 trial evaluating reduced-intensity conditioning before allogeneic donor stem cell transplantation in patients with high-risk hematol…

• CLINICAL_TRIALS research · 2025-10-30
  Clinical Trial Update: Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma [Phase 1, Phase 2]

  The document announces a planned Phase 1/2 clinical trial evaluating the combination of belantamab mafodotin and elotuzumab for multiple mye…

• CLINICAL_TRIALS research · 2025-10-30
  Clinical Trial Update: Two Step Haplo With Radiation Conditioning [Phase 2]

  Phase 2 clinical trial update describing two-step haploidentical transplantation with radiation conditioning for hematologic diseases, curre…

• CLINICAL_TRIALS research · 2025-10-29
  Clinical Trial Update: Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 1]

  Phase 1 clinical trial investigating radioimmunotherapy with 111In/225Actinium-DOTA-daratumumab for relapsed/refractory multiple myeloma is …

• CLINICAL_TRIALS research · 2025-10-29
  Clinical Trial Update: Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders [Phase 1, Phase 2]

  A Phase 1/2 clinical trial is comparing subcutaneous daratumumab administration in the thigh versus the abdomen for plasma cell disorders, c…

• CLINICAL_TRIALS trial_result · 2025-10-27
  Clinical Trial Update: Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma [NA]

  This trial evaluated scalp cooling to prevent hair loss in patients undergoing stem cell transplantation for multiple myeloma, with results …

• FDA approval · 2025-10-23
  FDA Approved: BLENREP — Original Application (GlaxoSmithKline LLC)

  FDA approved BLENREP (belantamab mafodotin) via its original application. It is indicated for adults with relapsed or refractory multiple my…

• CLINICAL_TRIALS trial_result · 2025-10-22
  Clinical Trial Update: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma [Phase 1, Phase 2]

  This clinical trial update reports the termination of a Phase 1/2 study of INCB000928 in myelodysplastic syndromes and multiple myeloma, wit…

• CLINICAL_TRIALS trial_result · 2025-10-21
  Clinical Trial Update: A Study of Colesevelam for Lenalidomide-Associated Diarrhea [Phase 2]

  A Phase 2 study evaluating colesevelam for lenalidomide-associated diarrhea in multiple myeloma patients has completed, with results posted.

• CLINICAL_TRIALS trial_result · 2025-10-21
  Clinical Trial Update: High Dose Ascorbic Acid for Plasma Cell Disorders [Phase 1]

  Phase 1 trial evaluating high-dose ascorbic acid (vitamin C) in multiple myeloma has completed.

• CLINICAL_TRIALS withdrawal · 2025-10-21
  Clinical Trial Update: Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma [Phase 2]

  This clinical trial update reports the termination of a Phase 2 salvage therapy trial using daratumumab, ixazomib, pomalidomide, and dexamet…

• CLINICAL_TRIALS research · 2025-10-21
  Clinical Trial Update: Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL [Phase 1]

  Phase 1 clinical trial update for Kappa-CD28 T lymphocytes in chronic lymphocytic leukemia, B-cell lymphoma, and multiple myeloma. The study…